{
  "id": 16736654,
  "title": "Merakris Advances Potentially Pivotal MTX-001 Phase 2/3 Strategy Following FDA Pre-IND Meeting",
  "url": "https://urgent.news/2026/10/27/merakris-advances-potentially-pivotal-mtx-001-phase-2-3-strategy",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-27T10:38:39.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/merakris-advances-potentially-pivotal-mtx-001-phase-2-3-strategy-following-fda-pre-ind-meeting"
  },
  "original_language": "en",
  "account": null,
  "summary": "FDA indicates proposed double-blind Phase 2/3 design could be considered adequate and well controlled as Merakris prepares its first commercial-pilot GMP drug lot for a potentially pivotal trial. RESEARCH TRIANGLE PARK, N.C., Oct. 27, 2026 (GLOBE NEWSWIRE) — Merakris Therapeutics, Inc., a clinical-stage biotechnology company developing regenerative biologic medicines, today announced receipt of…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}